Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Pembrolizumab (Keytruda) Combined With Decitabine and Pralatrexate in PTCL and CTCL Phase 1b international Investigator Sponsored Study; NCT03240211.
3 cohorts
- Pembrolizumab plus Pralatrexate
- Pembrolizumab plus Pralatrexate plus Decitabine
- Pembrolizumab plus Decitabine

Sponsor: Owen A. O'Connor, Columbia University
Collaborators:
University of Bologna
Samsung Medical Center
Merck Sharp & Dohme Corp.

Never thought I'd say immunotherapy and Folotyn in the same sentence. Early and Ph 1b and not recruiting yet but still pretty neat. Merck is involved but Spectrum is not (who's paying for Folotyn)? Dr O'Conner must really like Folotyn. His group is the one running the Folotyn/Romidepsin combo trial that showed good interim results.

Edit -

Never thought I'd say immunotherapy and Folotyn in the same sentence

Actually, I think I said it once before for NCT03161223; Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma